S&P ASX All Technology

US Dollar vs AUD

Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.

Get Started

SONN Sonnet BioTherapeutics Holdings Inc

1.57

-0.02 (-1.26%)

05 Feb 2025 - Closed

Delayed by 15 minutes

Form EFFECT - Notice of Effectiveness

Sonnet BioTherapeutics (NASDAQ:SONN)
Historical Stock Chart
From Jan 2025 to Feb 2025

Click Here for more Sonnet BioTherapeutics Charts.

Sonnet BioTherapeutics (NASDAQ:SONN)
Historical Stock Chart
From Feb 2024 to Feb 2025

Click Here for more Sonnet BioTherapeutics Charts.

Sonnet BioTherapeutics Holdings Inc News

Form EFFECT - Notice of Effectiveness
Monday 3 February 2025 (2 days ago) • Edgar (US Regulatory)

Form 424B3 - Prospectus [Rule 424(b)(3)]
Saturday 1 February 2025 (4 days ago) • Edgar (US Regulatory)

Form 424B3 - Prospectus [Rule 424(b)(3)]
Saturday 1 February 2025 (4 days ago) • Edgar (US Regulatory)

Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]
Friday 31 January 2025 (5 days ago) • Edgar (US Regulatory)

Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]
Friday 31 January 2025 (5 days ago) • Edgar (US Regulatory)

Form 8-K - Current report
Wednesday 29 January 2025 (1 week ago) • Edgar (US Regulatory)

Sonnet BioTherapeutics Further Expands Global Intellectual Property Portfolio with Issuance of EU Patent for FHAB® Platform Technology
Wednesday 29 January 2025 (1 week ago) • GlobeNewswire Inc.

Form S-1 - General form for registration of securities under the Securities Act of 1933
Thursday 23 January 2025 (2 weeks ago) • Edgar (US Regulatory)

Form S-1 - General form for registration of securities under the Securities Act of 1933
Thursday 23 January 2025 (2 weeks ago) • Edgar (US Regulatory)

Sonnet BioTherapeutics to Present at LIVE! with Webull Corporate Connect: Healthcare Investment Webinar
Thursday 23 January 2025 (2 weeks ago) • GlobeNewswire Inc.

Form 8-K - Current report
Wednesday 22 January 2025 (2 weeks ago) • Edgar (US Regulatory)

Sonnet BioTherapeutics Expands Phase 1 SB101 Trial to Evaluate Combination of SON-1010 with Trabectedin in Certain Sarcomas
Wednesday 22 January 2025 (2 weeks ago) • GlobeNewswire Inc.

More Sonnet BioTherapeutics Holdings Inc News Articles

abrdn Emerging Markets E...

Suez Environnement Compa...

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions